Related Experiment Video

Updated: Dec 26, 2025

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.0K

Toxicity of Metformin and Hypoglycemic Therapies

Muhammad S Akhter1, Priyasha Uppal2

  • 1Mount Sinai Beth Israel/Icahn School of Medicine at Mount Sinai, New York, NY.

Advances in Chronic Kidney Disease
|March 10, 2020
PubMed

Insights

Metformin and other diabetes drugs help manage type 2 diabetes. However, kidney disease requires careful dosing and monitoring to prevent toxicity and serious side effects from these medications.

Area of Science:

  • Endocrinology
  • Nephrology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus is a prevalent condition requiring pharmacologic management.
  • Antidiabetic medications, including metformin, are cornerstone therapies.
  • Kidney function is crucial for the safe and effective use of many antidiabetic agents.

Purpose of the Study:

  • To review the available literature on the adverse events and toxicity of hypoglycemic therapies.
  • To highlight the importance of renal dosing and kidney function monitoring in patients with kidney disease.
  • To identify scenarios requiring caution when using antidiabetic medications in patients with renal impairment.

Main Methods:

  • Literature review of studies on antidiabetic medications and kidney disease.
  • Analysis of incidence of adverse events and toxicity.
  • Evaluation of renal dosing guidelines and monitoring practices.

Main Results:

  • Metformin and other antidiabetic drugs offer benefits but necessitate careful consideration in renal impairment.
  • Renal dosing, kidney function monitoring, and risk assessment for side effects are essential.
  • Specific agents require heightened vigilance to avoid toxicity.

Conclusions:

  • Judicious use of antidiabetic medications in patients with kidney disease is paramount.
  • Individualized treatment plans incorporating renal parameters are necessary.
  • Ongoing monitoring is critical to ensure patient safety and therapeutic efficacy.
Keywords:
Adverse effectsChronic kidney diseaseDiabetes mellitusSafetyToxicity

More Related Videos

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.2K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.8K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
533
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
727
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
662
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
468
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
786
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
510